PYC Therapeutics

Focus: PYC Therapeutics is an Australian biotech company specializing in peptide drug discovery for rare genetic diseases in ophthalmology and nephrology. The company operates at pre-revenue stage with an early-stage pipeline focused on inherited retinal dystrophies and polycystic kidney disease.

Ophthalmology Nephrology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About PYC Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow PYC Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Natural History of PRPF31 Mutation-Associated Retinal Dystrophy

Retinitis Pigmentosa

N/A

Clinical Trials (1)

NCT05573984Natural History of PRPF31 Mutation-Associated Retinal Dystrophy

N/A

Help build intelligence for PYC Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused peptide platform with clear therapeutic areas (ophthalmology/nephrology) offers deep technical expertise in a differentiated modality
Early-stage pipeline with multiple Phase 1/2 programs provides opportunity to shape drug development strategy and see projects advance
Rare disease focus (retinitis pigmentosa, ADOA, ADPKD) creates less competitive patient populations and potential for accelerated pathways

Watch Out For

Zero current job openings and no disclosed funding indicate the company may be operating in stealth mode or at minimal capacity
No approved products, limited publications (0), and early-phase trials suggest minimal near-term revenue catalysts or clinical validation
Australia-based headquarters may limit visa sponsorship options and reduce access to major pharma talent pools and networking

Generated by Claude from PYC Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Autosomal Dominant Optic Atrophy

N/A

Clinical Trials (1)

NCT06140329Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

N/A

VP-001

Retinal Dystrophy

Phase 1

Clinical Trials (1)

NCT05902962SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Phase 1

PYC-001

OPA1 Gene Mutation

Phase 1

Clinical Trials (1)

NCT06461286SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)

Phase 1

VP-001

Retinitis Pigmentosa 11

Phase 1

Clinical Trials (1)

NCT06455826MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

Phase 1

PYC-003

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Phase 1

Clinical Trials (1)

NCT06714006Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003

Phase 1

VP-001

Retinitis Pigmentosa 11

Phase 1/2

Clinical Trials (1)

NCT06852963A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Phase 1/2

PYC-001

OPA1 Gene Mutation

Phase 1/2

Clinical Trials (1)

NCT06970106Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)

Phase 1/2